Parkin, DM, Bray, FI, Devesa, SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (Suppl 8yes): S4–S66.
Bosch, FX, Lorincz, A, Munoz, N, Meijer, CJ, Shah, KV.The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–265.
Ferlay, J, Bray, F, Pisani, P, Parkin, DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. IARC Press, Lyon, 2004 (http://www-depdb.iarc.fr/globocan/GLOBOframe.htm). Accessed 2 July 2005.
Sanders, GD, Taira, AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37–48.
Kiviat, N, Koutsky, LA, Paavonen, J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes, KK, Sparling, PF, Mardh, P-A, Lemon, SM, Stamm, WE, Piot, P, Wasserheit, JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669–684.
Zheng, T, Holford, TR, Ma, Z, Chen, Y, Liu, W, Ward, BA, Boyle, P. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 1996; 25: 252–258.
Sasieni, P, Adams, J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357: 1490–1493.
Franco, EL, Duarte-Franco, E, Ferenczy, A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001; 164: 1017–1025.
Lehtinen, M, Paavonen, J. Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS 2001; 12: 771–776.
Gillison, ML, Shah, KV. Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003; 31: 57–65.
Woodman, CB, Collins, S, Winter, H, et al. . Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831–1836.
Burk, RD, Kelly, P, Feldman, J, et al. . Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23: 333–341.
Dillner, J, Kallings, I, Brihmer, C, et al. . Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 1394–1398.
Koutsky, LA, Kiviat, NB. Genital human papillomaviruses. In: Holmes, KK, Sparling, PF, Mardh, P-A, Lemon, SM, Stamm, WE, Piot, P, Wasserheit, JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669–684.
Kjaer, SK, van den Brule, AJ, Paull, G, et al. . Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572.
Karlsson, R, Jonsson, M, Edlund, K, et al. . Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995; 22: 119–127.
Ho, GY, Bierman, R, Beardsley, L, Chang, CJ, Burk, RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–428.
Franco, EL, Villa, LL, Sobrinho, JP, et al. . Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415–1423.
Herrero, R, Hildesheim, A, Bratti, C, et al. . Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 464–474.
Rousseau, MC, Villa, LL, Costa, MC, Abrahamowicz, M, Rohan, TE, Franco, E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003; 30: 581–587.
Elfgren, K, Kalantari, M, Moberger, B, Hagmar, B, Dillner, J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183: 561–567.
Galloway, DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 3: 469–475.
Ho, GY, Burk, RD, Klien, S, et al. . Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365–1371.
Bosch, FX, Manos, MM, Munoz, N, et al. . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796–802.
Munoz, N, Bosch, FX, de Sanjose, S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–527.
Lehtinen, M, Paavonen, J. Effectiveness of preventive human papillomavirus vaccination. Int J STD & AIDS 2003; 14: 787–792.
Anttila, T, Saikku, P, Koskela, P, et al. . Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc 2001; 285: 47–51.
Smith, JS, Munoz, N, Herrero, R, et al. . Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324–331.
Lehtinen, M, Koskela, P, Jellum, E, et al. . Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol 2002; 156: 687–692.
Smith, JS, Herrero, R, Bosetti, C, et al. .; International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604–1613.
Zenilman, JM. Chlamydia and cervical cancer: a real association? J Am Med Assoc 2001; 285: 81–83.
Hemminki, K, Dong, C, Vaittinen, P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer 1999; 82: 775–781.
Castellsague, X, Bosch, FX, Munoz, N, et al. .; International Agency for research on Cancer Multicenter Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105–1112.
Solomon, D, Davey, D, Kurman, R, et al. .; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J Am Med Assoc 2002; 287: 2114–2119.
Gustafsson, L, Ponten, J, Zack, M, Adami, HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755–763.
Levi, F, Lucchini, F, Negri, E, Franceschi, S, la Vecchia, C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000; 36: 2266–2271.
Martin-Hirsch, PL, Koliopoulos, G, Paraskevaidis, E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. Eur J Gynaecol Oncol 2002; 23: 363–365.
Hakama, M, Hristova, L. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life. Acta Oncol 1998; 36: 1–160.
Peto, J, Gilham, C, Fletcher, O, Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–256.
Nanda, K, McCrory, DC, Myers, ER, et al. . Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810–819.
Crum, CP. The beginning of the end for cervical cancer? N Engl J Med 2002; 347: 1703–1705.
European Commission DG V F.2. ‘Europe against cancer’ programme/Committee on quality assurance, training and education of the European Federation of Cytology Societies (QUATE). European guidelines for quality assurance in cervical cancer screening, CRSG, 1997 (Technical editor: Dr Chris de Woolf). (http://crsg.ubc.kun.nl/quate/Guidelines/euindex.html). Accessed 15 December 2002.
Laukkanen, P, Koskela, P, Pukkala, E, et al. . Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105–2109.
Goldie, SJ, Kuhn, L, Denny, L, Pollack, A, Wright, TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. J Am Med Assoc 2001; 285: 3107–3115.
Cuzick, J, Szarewski, A, Cubie, H, et al. . Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871–1876.
Kulasingam, SL, Hughes, JP, Kiviat, NB, et al. . Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. J Am Med Assoc 2002; 288: 1749–1757.
Wright, TC Jr., Cox, JT, Massad, LS, Twiggs, LB, Wilkinson, EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. J Am Med Assoc 2002; 287: 2120–2129.
Peto, J, Gilham, C, Deacon, J, et al. . Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942–953.
Koutsky, LA, Ault, KA, Wheeler, CM, et al. . A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–1651.
Harper, DM, Franco, EL, Wheeler, C, et al. .; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–1765.
Lehtinen, M, Paavonen, J. Vaccination against human papillomaviruses shows great promise. Lancet 2004; 364: 1731–1732.
Schiller, JT, Davies, P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343–347.
Villa, LL, Costa, RL, Petta, CA, et al. . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–278.
Davidson, EJ, Boswell, CM, Sehr, P, et al. . Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032–6041.
Kirnbauer, R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996; 39: 54–61.
Munoz, N, Bosch, FX, Castellsague, X, et al. . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278–285.
Liaw, KL, Hildesheim, A, Burk, RD, et al. . A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8–15.
Ho, GY, Studentsov, Y, Hall, CB, et al. . Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186: 737–742.
Thomas, KK, Hughes, JP, Kuypers, JM, et al. . Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 1097–1102.
Luostarinen, T. No excess risk of cervical carcinoma among women seropostiive for both HPV-16 and HPV6/11. Int J Cancer 1999; 80: 818–822.
Lipsitch, M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997; 94: 6571–6576.
Garnett, GP, Waddell, HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000; 19: 101–111.
Hughes, JP, Garnett, GP, Koutsky, L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631–639.
Goldie, SJ, Grima, D, Kohli, M, Wright, TC, Weinstein, M, Franco, E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896–904.
Sasieni, PD, Cuzick, J, Lynch-Farmery, E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996; 73: 1001–1005.
Kulasingam, SL, Myers, ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003; 290: 781–789.
Whittle, H, Jaffar, S, Wansbrough, M, et al. . Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325: 569.
Stone, KM, Karem, KL, Sternberg, MR, et al. . Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 1396–1402.
Winer, RL, Lee, SK, Hughes, JP, Adam, DE, Kiviat, NB, Koutsky, LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218–226.
Taira, AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915–1923.
Stanberry, LR, Spruance, SL, Cunningham, AL, et al. .; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652–1661.
Waller, J, McCaffery, K, Nazroo, J, Wardle, J. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 2005; 92: 265–270.
Rose, RC, White, WI, Li, M, Suzich, JA, Lane, C, Garcea, RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998; 72: 6151–6154.
Gerber, S, Lane, C, Brown, DM, et al. . Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001; 75: 4752–4760.